{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:43:25Z","timestamp":1792601005668,"version":"4.5.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100022107","name":"Universit\u00e9 de Limoges","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100022107","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>An increasing number of anecdotal reports on social media platforms and medical blogs describe dysesthesia, particularly burning skin sensations, in association with glucagon-like peptide-1 receptor (GLP-1R) agonists. We performed a pharmacovigilance data-mining analysis to characterise cases of dysesthesia related to GLP-1R.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a disproportionality analysis using VigiBase data on GLP-1R (Anatomical Therapeutic Chemical classification: ATC code A10BJ) and tirzepatide, focusing on the HLT (High Level Term) \u201cParaesthesia and dysesthesia\u201d, with the Information Component (IC). Additionally, we reviewed all narratives of dysesthesia cases in the French Pharmacovigilance database to extract clinical and pharmacological characteristics. A literature review complemented this analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Exenatide was significantly associated with hypoesthesia or oral paraesthesia, semaglutide and tirzepatide with hyperaesthesia, and semaglutide with dysesthesia and burning sensation. Dysesthesia appears to be dose-dependent, occurring more frequently at higher doses and with more potent GLP-1R, whether used for weight management or type 2 diabetes. Discontinuation was often performed, followed by spontaneous favourable outcomes, and cases of rechallenge were observed. Skin burning sensations represent a distinctive form of dysesthesia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Pharmacovigilance quantitative and qualitative data strengthens evidence for dysesthesias associated with GLP-1R agonists already observed in clinical trials of semaglutide, tirzepatide, and retatrutide.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00228-026-04079-7","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:05:12Z","timestamp":1779408312000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Dysesthesia associated with GLP-1 agonist therapies: data-mining analysis and literature review"],"prefix":"10.1007","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4344-0359","authenticated-orcid":false,"given":"Marie-Laure","family":"Laroche","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1447-8534","authenticated-orcid":false,"given":"H\u00e9l\u00e8ne","family":"G\u00e9niaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2813-1566","authenticated-orcid":false,"given":"Manon","family":"Jardou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,22]]},"reference":[{"key":"4079_CR1","doi-asserted-by":"publisher","unstructured":"Zheng Z et al (2024) Sep., \u2018Glucagon-like peptide-1 receptor: mechanisms and advances in therapy.\u2019, Signal Transduct. Target. Ther., vol. 9, no. 1, p. 234. https:\/\/doi.org\/10.1038\/s41392-024-01931-z","DOI":"10.1038\/s41392-024-01931-z"},{"key":"4079_CR2","doi-asserted-by":"publisher","unstructured":"Drucker DJ, Holst JJ (2023) \u2018The expanding incretin universe: from basic biology to clinical translation.\u2019, Diabetologia, vol. 66, no. 10, pp. 1765\u20131779, Oct. https:\/\/doi.org\/10.1007\/s00125-023-05906-7","DOI":"10.1007\/s00125-023-05906-7"},{"key":"4079_CR3","doi-asserted-by":"publisher","unstructured":"Ismaiel A et al \u2018Gastrointestinal adverse events associated with GLP-1 RA in non-diabetic patients with overweight or obesity: a systematic review and network meta-analysis.\u2019, Int. J. Obes. (2005), vol. 49, no. 10, pp. 1946\u20131957, Oct. 2025, doi:, vol. 49, no. 10, pp. 1946\u20131957, Oct. 2025. https:\/\/doi.org\/10.1038\/s41366-025-01859-6","DOI":"10.1038\/s41366-025-01859-6"},{"key":"4079_CR4","doi-asserted-by":"publisher","unstructured":"Chen H et al (May 2025) Pharmacovigilance analysis of neurological adverse events associated with GLP-1 receptor agonists based on the FDA Adverse Event Reporting System. Sci Rep 15(1):18063. https:\/\/doi.org\/10.1038\/s41598-025-01206-9","DOI":"10.1038\/s41598-025-01206-9"},{"key":"4079_CR5","doi-asserted-by":"publisher","unstructured":"Okawa T et al (Feb. 2014) Sensory and motor physiological functions are impaired in gastric inhibitory polypeptide receptor-deficient mice. J Diabetes Investig 5(1):31\u201337. https:\/\/doi.org\/10.1111\/jdi.12129","DOI":"10.1111\/jdi.12129"},{"key":"4079_CR6","doi-asserted-by":"crossref","unstructured":"Siddeeque N et al (Dec. 2024) Neuroprotective effects of GLP-1 receptor agonists in neurodegenerative Disorders: A Large-Scale Propensity-Matched cohort study. Int Immunopharmacol 143:113537. no. Pt 310.1016\/j.intimp.2024.113537","DOI":"10.1016\/j.intimp.2024.113537"},{"key":"4079_CR7","doi-asserted-by":"publisher","unstructured":"Labib A, Burke O, Nichols A, Maderal AD (2023) \u2018Approach to diagnosis, evaluation, and treatment of generalized and nonlocal dysesthesia: A review.\u2019, J. Am. Acad. Dermatol., vol. 89, no. 6, pp. 1192\u20131200, Dec. https:\/\/doi.org\/10.1016\/j.jaad.2023.06.063","DOI":"10.1016\/j.jaad.2023.06.063"},{"key":"4079_CR8","doi-asserted-by":"publisher","unstructured":"Fusaroli M et al (2024) \u2018The Reporting of a Disproportionality Analysis for Drug Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Development and Statement.\u2019, Drug Saf., vol. 47, no. 6, pp. 575\u2013584, Jun. https:\/\/doi.org\/10.1007\/s40264-024-01421-9","DOI":"10.1007\/s40264-024-01421-9"},{"key":"4079_CR9","doi-asserted-by":"publisher","unstructured":"Lindquist M (2008) \u2018VigiBase, the WHO Global ICSR Database System: Basic Facts\u2019, Drug Inf. J. DIJ Drug Inf. Assoc., vol. 42, no. 5, pp. 409\u2013419, Sep. https:\/\/doi.org\/10.1177\/009286150804200501","DOI":"10.1177\/009286150804200501"},{"key":"4079_CR10","doi-asserted-by":"publisher","unstructured":"Nor\u00e9n GN, Hopstadius J, Bate A (2013) \u2018Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery.\u2019, Stat. Methods Med. Res., vol. 22, no. 1, pp. 57\u201369, Feb. https:\/\/doi.org\/10.1177\/0962280211403604","DOI":"10.1177\/0962280211403604"},{"key":"4079_CR11","doi-asserted-by":"publisher","unstructured":"Bate A et al (1998) \u2018A Bayesian neural network method for adverse drug reaction signal generation.\u2019, Eur. J. Clin. Pharmacol., vol. 54, no. 4, pp. 315\u2013321, Jun. https:\/\/doi.org\/10.1007\/s002280050466","DOI":"10.1007\/s002280050466"},{"key":"4079_CR12","doi-asserted-by":"publisher","unstructured":"Ahern S (2025) \u2018Allodynia and Dysesthesia Associated With Semaglutide and Tirzepatide\u2019, Cureus, vol. 17, no. 10, p. e94126, Oct. https:\/\/doi.org\/10.7759\/cureus.94126","DOI":"10.7759\/cureus.94126"},{"key":"4079_CR13","doi-asserted-by":"publisher","unstructured":"Stokes M, Linnebur SA, Tietz S, Fixen DR (Mar. 2025) A Case of Semaglutide-Induced Skin Burning. Ann Intern Med Clin Cases 4(3):e240568. https:\/\/doi.org\/10.7326\/aimcc.2024.0568","DOI":"10.7326\/aimcc.2024.0568"},{"key":"4079_CR14","doi-asserted-by":"publisher","unstructured":"Knop FK et al (2023) \u2018Oral semaglutide 50\u00a0mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial\u2019, The Lancet, vol. 402, no. 10403, pp. 705\u2013719, Aug. https:\/\/doi.org\/10.1016\/S0140-6736(23)01185-6","DOI":"10.1016\/S0140-6736(23)01185-6"},{"key":"4079_CR15","doi-asserted-by":"publisher","unstructured":"Tran MM, Mirza FN, Lee AC, Goldbach HS, Libby TJ, Wisco OJ (2024) \u2018Dermatologic findings associated with semaglutide use: A scoping review\u2019, J. Am. Acad. Dermatol., vol. 91, no. 1, pp. 166\u2013168, Jul. https:\/\/doi.org\/10.1016\/j.jaad.2024.03.021","DOI":"10.1016\/j.jaad.2024.03.021"},{"key":"4079_CR16","doi-asserted-by":"publisher","unstructured":"Wadden TA et al (2021) \u2018Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial\u2019, JAMA, vol. 325, no. 14, pp. 1403\u20131413, Apr. https:\/\/doi.org\/10.1001\/jama.2021.1831","DOI":"10.1001\/jama.2021.1831"},{"key":"4079_CR17","doi-asserted-by":"publisher","unstructured":"Aroda VR, J\u00f8rgensen NB, Kumar B, Lingvay I, Laulund AS, Buse JB (2025) \u2018High-Dose Semaglutide (Up to 16\u00a0mg) in People With Type 2 Diabetes and Overweight or Obesity: A Randomized, Placebo-Controlled, Phase 2 Trial.\u2019, Diabetes Care, vol. 48, no. 6, pp. 905\u2013913, Jun. https:\/\/doi.org\/10.2337\/dc24-2425","DOI":"10.2337\/dc24-2425"},{"key":"4079_CR18","doi-asserted-by":"publisher","unstructured":"Wharton S et al (Nov. 2025) Once-weekly semaglutide 7\u00b72\u00a0mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial. Lancet Diabetes Endocrinol 13(11):949\u2013963. https:\/\/doi.org\/10.1016\/S2213-8587(25)00226-8","DOI":"10.1016\/S2213-8587(25)00226-8"},{"key":"4079_CR19","doi-asserted-by":"publisher","unstructured":"Lingvay I et al (2025) \u2018Once-weekly semaglutide 7\u00b72\u00a0mg in adults with obesity and type 2 diabetes (STEP UP T2D): a randomised, controlled, phase 3b trial\u2019, Lancet Diabetes Endocrinol., vol. 13, no. 11, pp. 935\u2013948, Nov. https:\/\/doi.org\/10.1016\/S2213-8587(25)00225-6","DOI":"10.1016\/S2213-8587(25)00225-6"},{"key":"4079_CR20","doi-asserted-by":"publisher","unstructured":"Jastreboff AM et al (2023) \u2018Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.\u2019, N. Engl. J. Med., vol. 389, no. 6, pp. 514\u2013526, Aug. https:\/\/doi.org\/10.1056\/NEJMoa2301972","DOI":"10.1056\/NEJMoa2301972"},{"key":"4079_CR21","doi-asserted-by":"publisher","unstructured":"Wharton S et al (2025) \u2018Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment.\u2019, N. Engl. J. Med., vol. 393, no. 18, pp. 1796\u20131806, Nov. https:\/\/doi.org\/10.1056\/NEJMoa2511774","DOI":"10.1056\/NEJMoa2511774"},{"key":"4079_CR22","doi-asserted-by":"publisher","unstructured":"Burke OM, Sa B, Cespedes DA, Tosti A (2025) \u2018Dermatologic Implications of Glucagon-Like Peptide-1 Receptor Agonist Medications\u2019, Skin Appendage Disord., vol. 11, no. 5, pp. 416\u2013423, Feb. https:\/\/doi.org\/10.1159\/000544023","DOI":"10.1159\/000544023"},{"key":"4079_CR23","doi-asserted-by":"publisher","unstructured":"de Sousa E, Sparks L, Townsend K (2025) \u2018Incretin Receptors in the Peripheral Nervous System: Implications for Obesity Treatment and Peripheral Neuropathy.\u2019, Diabetes, vol. 74, no. 8, pp. 1313\u20131319, Aug. https:\/\/doi.org\/10.2337\/db25-0158","DOI":"10.2337\/db25-0158"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04079-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-026-04079-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04079-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T06:16:55Z","timestamp":1781072215000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-026-04079-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,22]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["4079"],"URL":"https:\/\/doi.org\/10.1007\/s00228-026-04079-7","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,22]]},"assertion":[{"value":"6 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study, based on anonymized pharmacovigilance data and a literature review, is exempt from formal review by the Limoges University Hospital Institutional Review Board. The requirement for written informed consent was waived owing to the use of a population-level dataset.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to Participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"154"}}